Home Newsfeeds Citigroup Maintains Neutral on Teck Resources, Raises Price Target to C$64

Citigroup Maintains Neutral on Teck Resources, Raises Price Target to C$64

Citigroup analyst Alexander Hacking maintains Teck Resources (TSX:TECK) with a Neutral and raises the price target from C$55 to C$64.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Citigroup analyst Alexander Hacking maintains Teck Resources (TSX:TECK) with a Neutral and raises the price target from C$55 to C$64.

Prologis Board of Directors Increase In Quarterly Common Stock Dividend From $0.79 To $0.87 Per Share

By Happy Mohamed

February 23, 6:05 PM

The Board of Directors of Prologis, Inc. (NYSE:PLD) today approved a plan to raise the company's annualized dividend by 10% to $3.48 per share of common stock. The board declared a regular cash

PLD

NeurAxis, Inc. Issues Letter To Shareholders From Brian Carrico, President And Chief Executive Officer

By Benzinga Newsdesk

December 20, 10:11 AM

NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults,

NRXS

US Stocks Mixed; SAIC Posts Upbeat Results

By Lisa Levin

June 5, 9:47 AM

U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to 13,251.38. The S&P 500, also rose, gaining, 0.13% to 4,288.00.

AMTX

EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target

By Benzinga Newsdesk

February 21, 5:35 AM

EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.

JSPR

Citigroup Maintains Neutral on Teck Resources, Raises Price Target to C$64

Related Posts

Prologis Board of Directors Increase In Quarterly Common Stock Dividend From $0.79 To $0.87 Per Share

NeurAxis, Inc. Issues Letter To Shareholders From Brian Carrico, President And Chief Executive Officer

US Stocks Mixed; SAIC Posts Upbeat Results

EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target